Eradication of Helicobacter pylori infection favourably affects altered gastric mucosal MMP-9 levels
article
Background: Helicobacter pylori gastritis is recognized as an important pathogenetic factor in peptic ulcer disease and gastric carcinogenesis, and is accompanied by strongly enhanced gastric mucosal matrix metalloproteinase-9 (MMP-9) levels. Aim: This study was performed to investigate whether H. pylori-affected gastric mucosal MMP-2 and MMP-9 levels are reversible by successful treatment of the infection. Patients and methods: Fifty-eight patients with H. pylori-associated gastritis were treated with a combination regimen of acid inhibitory therapy and antibiotics for 14 days. The levels and isoforms of MMP-2 and MMP-9 were measured by semiquantitative gelatin-zymography, bioactivity assay and enzyme-linked immunosorbent assay in gastric mucosal biopsy homogenates. Results: Latent, active, and total MMP-9 levels decreased consistently and significantly by successful H. pylori eradication, in antrum as well as corpus mucosa, compared with those prior to treatment, irrespective of the therapy regimen used. The elevated levels remained unchanged, however, when treatment failed. MMP-2 levels did not show major alterations after H. pylori therapy. Conclusion: Elevated MMP-9 levels in H. pylori-infected gastric mucosa are reversible by eradication of the infection. No major changes in mucosal MMP-2 levels were observed by H. pylori eradication. © 2007 The Authors.
Topics
Biomedical ResearchBioactivity assay (BIA)ELISAGastritisHelicobacter pyloriMatrix metalloproteinasesMMP-2 (gelatinase A)MMP-9 (gelatinase B)ZymographyAntibiotic agentClarithromycinGelatinGelatinase AGelatinase BMetronidazoleOmeprazoleProton pump inhibitorRanitidineAdultAgedControlled studyDrug activityEnzyme analysisEnzyme linked immunosorbent assayEradication therapyFemaleHelicobacter infectionHelicobacter pyloriHumanMajor clinical studyMalePriority journalQuantitative analysisStatistical significanceStomach mucosaZymographyAdultAgedAnti-Infective AgentsAnti-Ulcer AgentsBiopsyClarithromycinDrug Therapy, CombinationEndoscopy, GastrointestinalEnzyme-Linked Immunosorbent AssayFemaleGastric MucosaHelicobacter InfectionsHelicobacter pyloriHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MetronidazoleMiddle AgedOmeprazoleRanitidineTreatment OutcomeHelicobacter pylori
TNO Identifier
240229
ISSN
10834389
Source
Helicobacter, 12(5), pp. 498-504.
Pages
498-504
Files
To receive the publication files, please send an e-mail request to TNO Repository.